Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 1.00 |
| ▸ | FAAH | O00519 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 7/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 7/20 | 0.46 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SQOR | Q9Y6N5 | 3/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8161678 | 1.00 | NAAA (1.00) | NAAAFAAHL3MBTL1MEN1KMT2A | |
| SCHEMBL8156484 | 1.00 | NAAA (1.00) | NAAAFAAHL3MBTL1MEN1KMT2A | |
| SCHEMBL8156721 | 1.00 | NAAA (1.00) | NAAAFAAHL3MBTL1MEN1KMT2A | |
| SCHEMBL11191345 | 0.91 | NAAA (0.83) | NAAAFAAHTDP1HSD17B10GAA | |
| SCHEMBL11370007 | 0.88 | NAAA (0.77) | NAAAFAAHTDP1HSD17B10GAA | |
| SCHEMBL3392525 | 0.86 | NAAA (0.74) | NAAAFAAHMEN1KMT2ATDP1 | |
| SCHEMBL11197177 | 0.81 | NAAA (0.68) | NAAAFAAHHSD17B10GAA | |
| SCHEMBL24839166 | 0.80 | NAAA (0.65) | NAAAFAAHL3MBTL1MEN1KMT2A | |
| SCHEMBL11372041 | 0.78 | FAAH (0.64) | NAAAFAAHTDP1HSD17B10GAA | |
| SCHEMBL11059060 | 0.77 | NAAA (0.62) | NAAAFAAHTDP1HSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174015-B2 | Substituted heterocyclic derivative, preparation method and use thereof | XIAMEN UNIVERSITY (CN) | 2019-01-08 | — | — | US | disclosed |
| US-10174015-B2 | Substituted heterocyclic derivative, preparation method and use thereof | XIAMEN UNIVERSITY (CN) | 2019-01-08 | — | — | US | disclosed |
| US-20170334896-A1 | Substituted Heterocyclic Derivative, Preparation Method And Use Thereof | XIAMEN UNIVERSITY (CN) | 2017-11-23 | — | — | US | disclosed |
| US-20170334896-A1 | Substituted Heterocyclic Derivative, Preparation Method And Use Thereof | XIAMEN UNIVERSITY (CN) | 2017-11-23 | — | — | US | disclosed |
| US-20170334896-A1 | Substituted Heterocyclic Derivative, Preparation Method And Use Thereof | XIAMEN UNIVERSITY (CN) | 2017-11-23 | — | — | US | disclosed |
| CN-107074788-A | Substituted heterocyclic derivatives, preparation method and application thereof | 厦门大学 | 2017-08-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334896-A1 | Substituted Heterocyclic Derivative, Preparation Method And Use Thereof | FAAH, NAAA, FAAH2 | NAAA 2/4885FAAH 1/4885L3MBTL1 4849/4885 |
| US-10174015-B2 | Substituted heterocyclic derivative, preparation method and use thereof | DHPS, CYP3A5, CYP3A4 | NAAA 557/4885FAAH 934/4885L3MBTL1 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.